Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naronapride dose-finding phase IIb trial in idiopathic or diabetic gastroparesis
NL-OMON53662Phase 2Recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naronapride in gastroparesis, idiopathic gastroparesis (IG) and diabetic gastroparesis (4 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Change in ANMS GCSI-DD average weekly total symptom score. Started Jan 2024; status: recruiting.
02
Drugs
naronapride
03
Conditions
gastroparesisidiopathic gastroparesis (IG)diabetic gastroparesis
Beyond the preview
Go deeper on NL-OMON53662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53662.